SSA
DMRA

Schonfeld Strategic Advisors’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Buy
+10,824
New +$278K ﹤0.01% 1600

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Schonfeld Strategic Advisors's DMRA Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 10,824 shares worth $280K. The stake represents ﹤0.01% of the portfolio and ranks #1600 among its holdings.

65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Schonfeld Strategic Advisors held 10,824 shares of Damora Therapeutics, Inc. Ordinary Shares worth $280K as of Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1600 holding.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.